RP-323 is under clinical development by PhorMed and currently in the Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect RP-323’s likelihood of approval (LoA) and phase transition for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) took place on 05 Sep 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their RP-323 Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
RP-323 (TPA) is under development for the treatment of acute myelocytic leukemia (AML) in refractory patients, Hodgkin’s lymphoma, Parkinson's disease, stroke, COVID-19 associated acute respiratory distress syndrome (ARDS) and unspecified indication. It is administered through intravenous route. The drug candidate is 12-O-tetradecanoylphorbol-13-acetate which is a naturally occurring compound. It acts by targeting protein kinase C. It was also under development for the treatment of chronic myelocytic leukemia (CML, chronic myeloid leukemia), acute leukemia, non-Hodgkin lymphoma, aplastic anemia, chronic lymphocytic leukemia (CLL), myeloproliferative disorders and multiple myeloma (Kahler's disease) and myelodysplastic syndrome (MDS).
Quick View RP-323 LOA Data
|Highest Development Stage|